Exhibit 10.55 AMENDMENT TO LICENSE AND OPTION AGREEMENT (the "Amendment") This Amendment is effective as of the 8th day of April, 2002, by and between H.C. Implants B.V., a corporation duly organized and existing under the laws of the Netherlands,...License and Option Agreement • April 19th, 2002 • Osteotech Inc • Services-misc health & allied services, nec
CONFIDENTIAL TREATMENT REQUESTED LICENSE AND OPTION AGREEMENT between EMORY UNIVERSITY and ALIMERA SCIENCES, INC. for TRIPHENYLMETHANE COMPOUNDSLicense and Option Agreement • April 16th, 2010 • Alimera Sciences Inc • Pharmaceutical preparations • Georgia
THIS LICENSE AND OPTION AGREEMENT is made and entered into as of the 31st day of August, 2009, (hereinafter referred to as the “Effective Date”) by and between EMORY UNIVERSITY, a nonprofit Georgia corporation with offices located at 1599 Clifton Road NE, 4th Floor, Atlanta, Georgia 30322 (hereinafter referred to as “EMORY”) and Alimera Sciences, Inc., a Delaware corporation having a principal place of business located at 6120 Windward Parkway, Suite 290, Alpharetta, Georgia 30024 (hereinafter referred to as “ALIMERA”).
EX-10.2 2 dex102.htm LICENSE AND OPTION AGREEMENT, DATED AS OF APRIL 11, 2007 EXECUTION COPY Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting...License and Option Agreement • May 5th, 2020 • New York
Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
AMENDED AND RESTATED LICENSE AND OPTION AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and SURROZEN for Llama Single Domain Antibody Phage Library UC Case No. [****]License and Option Agreement • June 24th, 2021 • Consonance-HFW Acquisition Corp. • Biological products, (no disgnostic substances) • California
This amended and restated license and option agreement (“Agreement”) is effective this 17th day of January, 2020 (“Amended and Restated Effective Date”), between The Regents of the University of California (“The Regents”), a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, and acting through its Office of Technology Management, University of California San Francisco, 600 16th Street, Suite S-272, San Francisco, CA 94143 and Surrozen, Inc., a Delaware corporation, having a principal place of business at171 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080 (“Surrozen”). The Regents and Surrozen are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AND OPTION AGREEMENT BY AND BETWEEN MEDIMMUNE, LLC AND BULLDOG PHARMACEUTICALS, INC.License and Option Agreement • September 12th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations • New York
This License and Option Agreement (this “Agreement”) is entered into and made effective as of the 24th day of July, 2013 (the “Effective Date”), by and between MedImmune, LLC, a limited liability company organized and existing under the laws of Delaware, having a principal office located at One MedImmune Way, Gaithersburg, MD 20878 (“MedImmune”), and Bulldog Pharmaceuticals, Inc., a company organized and existing under the laws of the British Virgin Islands, having a registered office located at Midocean Chambers, Road Town, Tortola, British Virgin Islands (“Kolltan”). MedImmune and Kolltan are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
ContractLicense and Option Agreement • March 21st, 2024 • Autolus Therapeutics PLC • Biological products, (no disgnostic substances)
LICENSE AND OPTION AGREEMENT by and between SPARK THERAPEUTICS, INC. and SELECTA BIOSCIENCES, INC. December 2, 2016License and Option Agreement • February 14th, 2017 • Selecta Biosciences Inc • Pharmaceutical preparations • New York
This License and Option Agreement (hereinafter “Agreement”), effective as of December 2, 2016 (the “Effective Date”), is made by and between Spark Therapeutics, Inc., a Delaware corporation with corporate offices at 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (“Spark”) and Selecta Biosciences, Inc., a Delaware corporation with corporate offices at 480 Arsenal Street, Building One, Watertown, MA 02472 (“Selecta”) (each, a “Party” and collectively, the “Parties”).
LICENSE and OPTION AGREEMENT BRIGHAM YOUNG UNIVERSITY and ARIDIS, LLCLicense and Option Agreement • July 18th, 2018 • Aridis Pharmaceuticals, Inc. • Pharmaceutical preparations • Utah
This Agreement, effective July 29, 2005 is entered into between Brigham Young University, a Utah non-profit corporation and institution of higher education, with its principal campus and place of business located at Provo, Utah 84602 (referred to in this Agreement as “BYU”) and Aridis, LLC, a California corporation with its principal place of business located at 350 Cervantes Road, Portola Valley, CA 94028, (referred to in this Agreement as “LICENSEE”).
LICeNSE AND OPTION AGREEMENT BY AND BETWEENLicense and Option Agreement • November 9th, 2016 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This LICENSE AGREEMENT (this “Agreement”) is made and effective as of the Effective Date (as defined below) by and between TRACON Pharmaceuticals, Inc., a Delaware corporation (“TRACON”) and Janssen Pharmaceutica N.V. (“Janssen”). Each of TRACON and Janssen is sometimes referred to herein individually as a “Party” and collectively as the “Parties.” In the event a Party assigned the License and Option Agreement (as defined below) in its entirety prior to the Effective Date (as defined below) pursuant to Section 13.6 of the License and Option Agreement, or a lawful successor of a Party became bound by the License and Option Agreement prior to the Effective Date, the references to such Party in this Agreement shall be deemed to refer to such permitted assignee or lawful successor.
LICENSE AND OPTION AGREEMENT by and between SPARK THERAPEUTICS, INC. and SELECTA BIOSCIENCES, INC. December 2, 2016License and Option Agreement • February 28th, 2017 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This License and Option Agreement (hereinafter “Agreement”), effective as of December 2, 2016 (the “Effective Date”), is made by and between Spark Therapeutics, Inc., a Delaware corporation with corporate offices at 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (“Spark”) and Selecta Biosciences, Inc., a Delaware corporation with corporate offices at 480 Arsenal Street, Building One, Watertown, MA 02472 (“Selecta”) (each, a “Party” and collectively, the “Parties”).
AMENDMENT NO. 2 TO THE LICENSE AND OPTION AGREEMENTLicense and Option Agreement • May 11th, 2004 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances • California
THIS AMENDMENT NO. 2 TO THE LICENSE AND OPTION AGREEMENT (“Amendment”) is made and entered into as of December 6, 2002, by and among GeneSoft Pharmaceuticals, Inc., a Delaware corporation (the “GS”), and LG Life Sciences, Ltd., a corporation organized under the laws of the Republic of Korea (“LGLS”). Capitalized terms not otherwise defined in this Amendment shall have the meaning given them in that certain License and Option Agreement by and among GS and LGLS dated as of October 22, 2002 (the “Agreement”).
RECITALSLicense and Option Agreement • January 28th, 1997 • Antivirals Inc
LICENSE AND OPTION AGREEMENTLicense and Option Agreement • April 28th, 2023 • ImmunoGen, Inc. • Pharmaceutical preparations • New York
This LICENSE AND OPTION AGREEMENT (this “Agreement”) is entered into and made effective as of February 27, 2023 (the “Effective Date”), by and between ImmunoGen, Inc., a Massachusetts corporation, having its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451 (“ImmunoGen”), and Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, having its principal place of business at 50 Northern Avenue, Boston, MA 02210 (“Vertex”). ImmunoGen and Vertex will be referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT NO. 1 TO LICENSE AND OPTION AGREEMENTLicense and Option Agreement • May 11th, 2004 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances
THIS AMENDMENT NO. 1 TO LICENSE AND OPTION AGREEMENT (the “Amendment”) is made and entered into this 21st day of November, 2002 (the “Effective Date”) by and between GENESOFT PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 7300 Shoreline Court, South San Francisco, CA, USA 94080 (“GS”) and LG LIFE SCIENCES, LTD., a corporation organized under the laws of the Republic of Korea having its principal place of business at LG Twin Tower, 20 yoido-dong, Youngdungpo-gu, Seoul, 150-721, Republic of Korea (“LGLS”). LGLS and GS may be referred to herein individually as a “Party” and collectively as the “Parties.”
LICENSE AND OPTION AGREEMENTLicense and Option Agreement • November 9th, 2016 • Pfenex Inc. • Pharmaceutical preparations
This LICENSE AND OPTION AGREEMENT (the “Agreement”) is entered into as of July 27, 2016 (the “Effective Date”) by and between PFENEX INC., a Delaware corporation, with its principal place of business at 10790 Roselle Street, San Diego, CA 92121 (“Pfenex”), and JAZZ PHARMACEUTICALS IRELAND LIMITED, a limited liability company incorporated under the laws of Ireland, with a registered office at Fourth Floor, Connaught House, One Burlington Road, Dublin 4, Ireland (“Jazz”). Pfenex and Jazz are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT NO. 2 TO THE LICENSE AND OPTION AGREEMENTLicense and Option Agreement • December 3rd, 2004 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances • California
THIS AMENDMENT NO. 2 TO THE LICENSE AND OPTION AGREEMENT (“Amendment”) is made and entered into as of December 6, 2002, by and among GeneSoft Pharmaceuticals, Inc., a Delaware corporation (the “GS”), and LG Life Sciences, Ltd., a corporation organized under the laws of the Republic of Korea (“LGLS”). Capitalized terms not otherwise defined in this Amendment shall have the meaning given them in that certain License and Option Agreement by and among GS and LGLS dated as of October 22, 2002 (the “Agreement”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AND OPTION AGREEMENT BY AND BETWEEN MEDIMMUNE, LLC AND BULLDOG PHARMACEUTICALS, INC.License and Option Agreement • March 7th, 2018 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • New York
This License and Option Agreement (this “Agreement”) is entered into and made effective as of the 24th day of July, 2013 (the “Effective Date”), by and between MedImmune, LLC, a limited liability company organized and existing under the laws of Delaware, having a principal office located at One MedImmune Way, Gaithersburg, MD 20878 (“MedImmune”), and Bulldog Pharmaceuticals, Inc., a company organized and existing under the laws of the British Virgin Islands, having a registered office located at Midocean Chambers, Road Town, Tortola, British Virgin Islands (“Kolltan”). MedImmune and Kolltan are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
Amendment One to License and Option AgreementLicense and Option Agreement • March 1st, 2019 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
This Amendment One to License and Option Agreement (the “Amendment”) is effective as of January 15, 2019 (the “Amendment Effective Date”), by and between Janssen Pharmaceutica N.V. (“Janssen”) and TRACON Pharmaceuticals, Inc., a Delaware corporation (“Licensee”). Each of Janssen and Licensee is sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
INTRODUCTIONLicense and Option Agreement • November 20th, 1997 • Apollon Inc • Biological products, (no disgnostic substances) • Massachusetts
LICENSE AND OPTION AGREEMENT BY AND BETWEEN MOMENTA PHARMACEUTICALS, INC. AND CSL BEHRING RECOMBINANT FACILITY AG DATED AS OF JANUARY 4, 2017License and Option Agreement • May 5th, 2017 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This License and Option Agreement (the “Agreement”), executed as of January 4, 2017 (the “Execution Date”), is made by and between Momenta Pharmaceuticals, Inc., a Delaware corporation (“Momenta”), with its principal place of business at 675 West Kendall Street, Cambridge, MA 02142 USA, and CSL Behring Recombinant Facility AG, a Swiss company (“CSL”), with its principal place of business at Wankdorfstrasse 10, 3000 Bern 22, Switzerland. Momenta and CSL may each be referred to individually as a “Party” or, collectively, the “Parties”.
LICENSE AND OPTION AGREEMENTLicense and Option Agreement • February 5th, 2024 • Graphite Bio, Inc. • Biological products, (no disgnostic substances) • California
This License and Option Agreement (this “Agreement”) is entered into as of August 4, 2023 (the “Effective Date”), by and between Kamau Therapeutics, Inc., a corporation existing under the laws of Delaware, having a place of business at [***] (“Licensee”) and Graphite Bio, Inc. a corporation existing under the laws of Delaware, having a place of business at 201 Haskins Way, Suite 210, South San Francisco, CA 94080 (“Graphite”). Each of Licensee and Graphite is referenced herein as a “Party” and collectively, the “Parties.”
EXHIBIT 10.6 CONFIDENTIAL TREATMENT ---------------------- ORCHID BIOSCIENCES, INC. HAS REQUESTED THAT THE MARKED PORTIONS OF THIS DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. [*]...License and Option Agreement • February 18th, 2000 • Orchid Biosciences Inc • New Jersey
